In 15 years, we’ve raised $225 million, sequenced the myeloma genome, and opened 45 trials of 23 drugs – six approved by the FDA – which have doubled the life span of multiple myeloma patients. I’ve taken both Velcade and Revlimid, which we helped develop.
– Kathy Giusti